Poster Session
(To be presented on July 7 from 4:40-6:00 p.m. ET)

PO-001 Circulating tumor-tissue modified HPV DNA testing in the clinical workup of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV Study. Sana Batool. Harvard Medical School, Boston, MA, United States.


PO-003 Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009. Barbara Burtness. Yale Cancer Center, New Haven, CT, United States.

PO-004 Allogeneic memory-like natural killer (NK) cell therapy with IL-15 superagonist with or without ipilimumab for advanced, incurable head and neck cancer: a phase 1 trial. Glenn Hanna. Dana-Farber Cancer Institute, Boston, MA, United States.


PO-007 A phase 2 open-label study of conditionally active biologic, ozurifamab vedotin (BA3021) in PD-1/L1 failure patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Jacob Thomas. USC Norris Comprehensive Cancer Center, Los Angeles, CA, United States.

PO-008 Association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122. Jianda Yuan. Merck & Co., Inc., Rahway, NJ, United States.

PO-010 Operationalizing the health care system electronic medical record to create head and neck cancer research and screening databases. Lindsey Mortensen. University of Minnesota Medical School, Minneapolis, MN, United States.

PO-011 Analysis of nuclear receptor expression in head and neck cancer. Lindsey Mortensen. University of Minnesota Medical School, Minneapolis, MN, United States.

PO-012 Spatial transcriptomic analysis of HPV-related and HPV-unrelated head and neck squamous cell carcinoma. Thomas Barrett. Washington University School of Medicine, Saint Louis, MO, United States.

PO-013 Cooperative HPV and YAP-mediated oncogenic reprogramming of oral progenitors into cancer stem cells at single cell resolution. Farhoud Faraji. UC San Diego Health, La Jolla, CA, United States.

PO-014 The biologic significance of myofibroblasts in the tumor-associated stromal tissue: a proteogenomic analysis of patients with head and neck squamous cell carcinoma. Yosef Haque. University of Kansas Cancer Center, Kansas City, KS, United States.

PO-015 The genetic landscape of head and neck cancer using brush biopsy. Evit John. University of Texas MD Anderson Cancer Center, Houston, TX, United States.


PO-017 Targeting murine oral tumors by pharmacological inhibition of β-catenin/CBP epigenetic activity. Mohammed Muzamil Khan. Boston University, Boston, MA, United States.

PO-018 Pathological analysis of newly established immunocompetent mice with full HPV16 genome integration. Xue Li. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

PO-020 Gene regulatory network connectivity analysis identifies novel candidate effectors of HNSC tumorigenesis. Stefano Monti. Boston University, Boston, MA, United States.
PO-021 TCGA differentially expressed genes between Caucasians and African Americans at variable analytic stringencies. Frank Ondrey. University of Minnesota, Minneapolis, MN, United States.

PO-022 Characterizing genetic and molecular differences in head and neck cancer based on history of smoking. Nosayaba Osazuwa-Peters. Duke University School of Medicine, Durham, NC, United States.

PO-023 The AP-1 transcription factor component, JunB, regulates the expression of HPV genes in head and neck cancer. Hina Rehmani. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

PO-024 Analysis of the NOTCH pathway in HNSCC: A target with a wide prognostic and therapeutic potential. Iole Ribizzi-Akhtar. Brown University/Lifespan Cancer Institute, Providence, RI, United States.


PO-028 Clinical and genomic correlates of intratumoral HPV for oropharyngeal and cervical cancers. Emrullah Yilmaz. Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States.

PO-029 Evaluation of the efficacy of dynamic contrast-enhanced (DCE) MRI in identifying radiotherapy-induced changes in the vasculature of the mandible. Moamen Abobakr. MD Anderson Cancer Center, Houston, TX, United States.

PO-030 Analysis of Wnt beta-catenin signaling and immune checkpoint expression in HPV-Infected individuals with oropharyngeal cancer. Babajide Ajayi. Oncopreventives and system oncology research Laboratory Ajayi Crowther University, Oyo, Nigeria.

PO-032 Association of a polymorphic variant in JMJD1C with tumor recurrence after adjuvant chemoradiation therapy in head and neck squamous cell carcinoma. Sanjeevani Arora. Fox Chase Cancer Center, Philadelphia, PA, United States.

PO-033 Transcriptomic and epigenetic characterization of head and neck cancer xenografts treated with nimorazole-modified radiochemotherapy. María Besso. German Cancer Research Center (DKFZ), Heidelberg, Germany.

PO-034 Optimizing chemotherapeutic regimen through metabolic interrogation to maximize radiosensitizing effects in HNSCC. Yunyun Chen. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

PO-035 Immune profiles of long-term survivors of patients with head and neck squamous carcinoma on immune checkpoint inhibitor therapy. Brock Christensen. Dartmouth, Lebanon, NH, United States.

PO-036 A deep learning alternative to regional molecular testing for HPV status. Stephanie Craig. Queen’s University Belfast, Belfast, Ireland.

PO-037 Biomarkers for early diagnosis of human papillomavirus-related oropharyngeal cancer. Kristina Dahlstrom. Baylor College of Medicine, Houston, TX, United States.

PO-038 Metabolic-inflammatory investigation of head and neck cancer patient reported neuropsychological factors via multiomics integration of the plasma metabolome, lipidome, and circulating inflammation cytokines. Ronald Eldridge. Emory University, Atlanta, GA, United States.

PO-039 Discovery and validation of methylated DNA markers of human papillomavirus associated oropharyngeal squamous cell carcinoma. Benjamin Gochanour. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
PO-040 Comparing digital image analysis with a manual scoring approach for quantification of p63 and BRCA1 protein expression in oropharyngeal squamous cell carcinoma. Laura Graham. Queen's University Belfast, Belfast, Ireland.


PO-042 Next generation liquid biopsy for diagnosis and prognostication in HPV+OPSCC. Shun Hirayama. Mass Eye and Ear, Boston, MA, United States.

PO-043 Development of an automated multi-objective model utilizing delta radiomics to predict locoregional recurrence in head and neck cancer patients treated with primary radiation. Ethan Kallenberger. University of Kansas Medical Center-Department of Otolaryngology Head & Neck Surgery, Kansas City, KS, United States.

PO-044 Correlation between circulating tumor DNA and tumor volume in head and neck cancer. Oghenefejiro Okifo. Henry Ford Health System, Detroit, MI, United States.

PO-045 Utility of circulating tumor tissue modified viral (TTMV)-HPV DNA to resolve clinically indeterminate findings in patients following definitive treatment for HPV-driven oropharyngeal cancer. Scott Roof. Mount Sinai Hospital, New York, NY, United States.

PO-046 Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV DNA before head and neck cancer diagnosis. Edward Sim. Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, United States.

PO-047 A novel saliva miRNA panel of promising diagnostic biomarkers for oral cancer: the association of miR-21 with smoking history. Dimitra Vageli. Yale School of Medicine, New Haven, CT, United States.

PO-048 Baseline blood DNA methylation-based immune profiles are associated with survival outcomes in head and neck cancer patients on immune checkpoint therapy. Karl Kelsey. Brown University, Providence, RI, United States.

PO-049 The neural landscape is associated with functional outcomes for patients with oropharyngeal squamous cell carcinoma. Shajedul Islam. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
PO-050 Preliminary results from an early-phase, open-label study of tolinapant and radiation in cisplatin-ineligible patients with previously untreated, locally advanced head and neck cancer. Nicole Schmitt. Emory University, Atlanta, GA, United States.

PO-051 Changing the radiation and immune-oncology paradigm in patients with head and neck squamous cell carcinoma (HNSCC) with the radioenhancer NBTXR3: from bench to bedside. Colette Shen. University of North Carolina (UNC) Medical Center, Chapel Hill, NC, United States.

PO-053 Chemical suppression of DHFR induces NRF2 inhibition and tumor regression. Paul Zolkind. Washington University School of Medicine, St Louis, MO, United States.

PO-054 Nut carcinoma of larynx with aberrant LCA expression. A rare entity with diagnostic and therapeutic challenge. Vikas Arora. Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.


PO-057 Systemic delivery of miR-27a* using ultrasound-targeted microbubble cavitation causes tumor regression. Nikhil Chari. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

PO-058 Piloting a novel strategy to rapidly implement smoking cessation treatment for newly-diagnosed head and neck cancer patients. Andrew Day. University of Texas Southwestern Medical Center, Dallas, TX, United States.

PO-060 Novel combination of TRIP13 and Aurora kinase A inhibition demonstrated extensive DNA damage and immunogenic cell death in RB-deficient cancers. Soma Ghosh. M.D. Anderson Cancer Center, Houston, TX, United States.

PO-061 Utilizing T cell receptor-based therapy to treat anaplastic thyroid cancer. Shao-Hsi Hung. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

PO-062 Synergistic effect of cisplatin conjugated iron doped zinc oxide nanoparticles in patient derived primary cell lines of oral squamous cell carcinoma (OSCC). Rijma Khan. CECOS University of IT and Emerging Sciences, Peshawar, India.

PO-064 Natural history and risk factors for osteoradionecrosis development in head and neck cancer survivors. Abdallah Mohamed. MD Anderson Cancer Center, Houston, TX, United States.


PO-067 Personalized therapeutic mRNA nano-vaccines are effective accross multiple preclinical and translational models of head and neck cancer. Natalie Silver. Cleveland Clinic, Cleveland, OH, United States.

PO-068 Harmony between transdifferentiated neuron and immunosuppressive tumor microenvironment. Shamima Akhter. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

PO-069 On the cutting edge of the leading edge: DCLK1 mediates HNSCC locoregional invasion. Levi Arnold. University of Kansas Medical Center, Kansas City, KS, United States.


PO-071 Pseudonormal morphology of adenoid cystic carcinoma cells subverts the antitumor reactivity of immune cells. Rajdeep Chakraborty. Macquarie University, Sydney, NSW, Australia.

PO-072 Durvalumab in combination with radioactive iodine in recurrent/metastatic thyroid cancers: Update on clinical and correlative analyses. Antoine Desilets. Memorial Sloan Kettering Cancer Center, New York, NY, United States.
PO-074 The evolution of the tumor immune microenvironment in immunosuppressed patients with cutaneous squamous cell carcinoma. Frederico Gleber-Netto. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.


PO-076 Adrenergic regulation of the anti-tumor immune response in p53-deficient tumors. Shajedul Islam. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.


PO-078 Tissue-resident memory CD8+ T cells correlate with anti-PD-1 response in head and neck cancer and expand upon cDC1 activation in tumor-draining lymph nodes to overcome PD-1 resistance. Michihisa Kono. DANA-FARBER CANCER INSTITUTE, BOSTON, MA, United States.

PO-079 The impact of statin use on anti-PD-1 monotherapy for recurrent head and neck squamous cell carcinoma. Chareeni Kurukulasuriya. University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.


PO-081 Patterns of immune susceptibility in young, non-smoking, oral cancer patients. Maxwell Lee. Stanford University School of Medicine, Stanford, CA, United States.

PO-082 Antigen presentation and inflammatory effects on immunesurveillance: Window of opportunity metformin monotherapy trial for squamous cell carcinoma of the head and neck (HNSCC). Derek Mann. Thomas Jefferson University, Philadelphia, PA, United States.

PO-084 Deletion of Macrophage Migration Inhibitory Factor promotes antitumoral T cell infiltration and inhibits MDSC recruitment to the head and neck cancer microenvironment. Steve Oghumu. Ohio State University, Columbus, OH, United States.
PO-085 Inhibition of ATR as a therapeutic strategy to enhance immunotherapy in head and neck cancer. Abdullah Osman. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

PO-086 Generation of HPV-negative tobacco-associated oral cancer models using p53 and Cdkn2a mutant mice. Roberto Rangel. UT MD Anderson Cancer Center, Houston, TX, United States.

PO-087 Single-cell transcriptome analysis reveals functional changes in tumor-infiltrating macrophages after nutraceutical momordicine-I treatment in head and neck cancer. Ratna Ray. Saint Louis University, St. Louis, MO, United States.

PO-088 TRPV1+ sensory neurons provide a tumor supportive environment through recruitment of MDSCs. Anthony Restaino. Sanford Research, Sioux Falls, SD, United States.

PO-089 Opioid-mediated suppression of anti-tumor immunity via peripheral OPRM1 signaling in head and neck squamous cell carcinoma. Nicole Scheff. University of Pittsburgh, Pittsburgh, PA, United States.

PO-090 Characterizing the intra-tumoral microbiome of laryngeal squamous cell carcinoma. Natalie Silver. Cleveland Clinic, Cleveland, OH, United States.

PO-091 Leveraging tissue-resident CD103+ NK cells for adoptive cell therapy in head and neck cancer. John Sunwoo. Stanford University, Palo Alto, CA, United States.

PO-092 Molecular characterization of the salivary adenoid cystic carcinoma tumor immune landscape by anatomic subsite. Jason Tasoulas. The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.


PO-094 Cholinergic modulation of tumor infiltrating lymphocytes in oral squamous cell carcinoma. Ruth White. Columbia University Medical Center, New York, NY, United States.
PO-095 TGF-β carrying exosomes in plasma of HNSCC as potential biomarkers of disease progression in patients with HNSCC. Theresa Whiteside. Depts. of Pathology, Immunology and Otolaryngology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.

PO-096 Cytokines in the lumen of exosomes are undetectable by immunoassays distorting cytokine profiles in HNC patients and healthy donors. Theresa Whiteside. University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, United States.

PO-097 Tumor-associated extracellular vesicles from HPV+ oropharyngeal cancer lymphatic fluid trigger an anti-tumor response through activation of the cGAS-STING pathway. Zhongping Xu. Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

PO-098 Development of radioimmunotherapy using IL7 and FLT3 in a murine HPV related head and neck squamous cell carcinoma model. Justin Yu. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

PO-099 Short-term outcomes of an extended endoscopic endonasal resection of a clival giant cell tumor with adjuvant RANK-L inhibitor therapy: Case report. Myra Zaheer. George Washington University School of Medicine and Health Sciences, Washington, DC, United States.

PO-100 Fusobacterium nucleatum promotes Epithelial-Mesenchymal Transition (EMT) of Oral Squamous Cell Carcinoma (OSCC) via INHBA-dependent SMAD/Laminin332/PI3K/AKT pathway. Hengyan Zhu. The Chinese University of Hong Kong, Hong Kong, Hong Kong.